Bionomics Limited, an Australian and US-based clinical-stage biopharmaceutical company, focuses on discovering and developing new drug candidates to address central nervous system disorders and certain types of cancer. Their key drug candidate, BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, recently finished its phase 2 clinical trial for treating social anxiety disorder and post-traumatic stress disorder. Additionally, the company is working on BNC375, a small molecule therapeutics to help alleviate cognitive impairment in Alzheimer's patients. Other drugs in the pipeline include BNC101, a monoclonal antibody that completed phase 1 clinical trials targeting cancer stem cells, and BNC105, a vascular disrupting agent currently in phase 2 clinical trials for refractory colorectal cancer and phase 1 clinical trials for relapsed/refractory chronic lymphocytic leukemia. Bionomics Limited has a licensing agreement with Merck & Co., Inc. for one of their drugs. The company was founded in 1996 and is based in Eastwood, Australia.
Bionomics Limited's ticker is BNO
The company's shares trade on the ASX stock exchange
They are based in Eastwood, Australia
There are 11-50 employees working at Bionomics Limited
It is https://www.bionomics.com.au/
Bionomics Limited is in the Healthcare sector
Bionomics Limited is in the Biotechnology industry
The following five companies are Bionomics Limited's industry peers: